NASDAQ:GOVX GeoVax Labs (GOVX) Stock Price, News & Analysis $1.99 -0.08 (-3.86%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About GeoVax Labs Stock (NASDAQ:GOVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GeoVax Labs alerts:Sign Up Key Stats Today's Range$1.99▼$2.1450-Day Range$1.98▼$8.3552-Week Range$1.09▼$11.18Volume605,263 shsAverage Volume2.38 million shsMarket Capitalization$4.59 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company OverviewGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More… Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… GeoVax Labs Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks70th Percentile Overall ScoreGOVX MarketRank™: GeoVax Labs scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingGeoVax Labs has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeoVax Labs has only been the subject of 2 research reports in the past 90 days.Read more about GeoVax Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for GeoVax Labs are expected to grow in the coming year, from ($5.10) to ($0.86) per share.Price to Book Value per Share RatioGeoVax Labs has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GeoVax Labs' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.80% of the outstanding shares of GeoVax Labs have been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 24.93%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGeoVax Labs does not currently pay a dividend.Dividend GrowthGeoVax Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.80% of the outstanding shares of GeoVax Labs have been sold short.Short Interest Ratio / Days to CoverGeoVax Labs has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GeoVax Labs has recently decreased by 24.93%, indicating that investor sentiment is improving significantly. News and Social Media2.1 / 5News Sentiment0.77 News SentimentGeoVax Labs has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for GeoVax Labs this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, GeoVax Labs insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of GeoVax Labs is held by insiders.Percentage Held by InstitutionsOnly 6.09% of the stock of GeoVax Labs is held by institutions.Read more about GeoVax Labs' insider trading history. Receive GOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address GOVX Stock News HeadlinesGermany finds mpox infection in country contracted abroadOctober 22, 2024 | markets.businessinsider.comGeovax Labs Inc (GOVX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...October 10, 2024 | finance.yahoo.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 29, 2024 | Weiss Ratings (Ad)GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comCSL Limited (CSJ.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comGeoVax to Participate in Upcoming Investor Conferences in SeptemberSeptember 3, 2024 | globenewswire.comGeoVax Labs to raise $5M via private placementAugust 29, 2024 | msn.comGeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-MarketAugust 28, 2024 | globenewswire.comSee More Headlines GOVX Stock Analysis - Frequently Asked Questions How have GOVX shares performed this year? GeoVax Labs' stock was trading at $5.4150 at the beginning of the year. Since then, GOVX stock has decreased by 63.3% and is now trading at $1.99. View the best growth stocks for 2024 here. How were GeoVax Labs' earnings last quarter? GeoVax Labs, Inc. (NASDAQ:GOVX) released its earnings results on Tuesday, August, 6th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.57) by $0.58. The company had revenue of $0.30 million for the quarter. When did GeoVax Labs' stock split? GeoVax Labs shares reverse split before market open on Wednesday, January 31st 2024. The 1-15 reverse split was announced on Wednesday, January 31st 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of GeoVax Labs? Shares of GOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GeoVax Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that GeoVax Labs investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Lipocine (LPCN), Fortress Biotech (FBIO) and Ovid Therapeutics (OVID). Company Calendar Last Earnings8/06/2024Today10/29/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOVX CUSIPN/A CIK832489 Webwww.geovax.com Phone(678) 384-7220Fax678-384-7281Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+536.5%Consensus RatingBuy Rating Score (0-4)3.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-852.60% Return on Assets-326.87% Debt Debt-to-Equity RatioN/A Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual Sales$300,677.00 Price / Sales15.28 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.61Miscellaneous Outstanding Shares2,308,000Free Float7,909,000Market Cap$4.59 million OptionableNot Optionable Beta3.05 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:GOVX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.